Pancreatic Cancer Research

ResearcherYamaguchi UniversityActive in the last 2 years

Tomio Ueno

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5100971539, A5113666179. Sources: OpenAlex.

Their work

Papers
12 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
39
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 2 papers · 2015: none · 2016: 2 papers · 2017: 4 papers · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 12

  1. [Complete Response of Adrenal Metastasis from Pancreatic Cancer Achieved by Multimodal Therapy-A Case Report]. Last author PMID 41546315↗
  2. Inhibition of pancreatic cancer-cell growth and metastasis in vivo by a pyrazole compound characterized as a cell-migration inhibitor by an in vitro chemotaxis… Co-author DOI 10.1016/j.biopha.2022.113733↗
  3. [Five Cases of Ten-Year Survival after Surgical Treatment of Pancreatic Cancer in Yamaguchi Prefecture]. Co-author PMID 32156955↗
  4. Novel Indications for Surgical Resection of Metachronous Lung Metastases From Pancreatic Cancer After Curative Resection. First author DOI 10.1097/mcg.0000000000000551↗
  5. Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy. Co-author DOI 10.1097/mpa.0000000000000880↗
  6. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. Co-author DOI 10.1111/cas.13113↗
  7. Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer. Co-author DOI 10.1186/s13046-017-0509-1↗
  8. Calreticulin is highly expressed in pancreatic cancer stem-like cells. Co-author DOI 10.1111/cas.13061↗
  9. [A Case of Borderline Resectable Pancreatic Cancer Responding to Preoperative GEM plus Nab-PTX Combination Chemotherapy]. First author PMID 28133195↗
  10. A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer. Co-author DOI 10.1097/cji.0000000000000012↗
  11. Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer. Co-author DOI 10.1186/1479-5876-12-175↗
  12. Proteomic differential display identifies upregulated vinculin as a possible biomarker of pancreatic cancer. Co-author DOI 10.3892/or.2012.2004↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yoshitaro Shindo · 9 shared papers, 2014–2019 · strength 0.46
  2. Hiroto Matsui · 9 shared papers, 2014–2019 · strength 0.46
  3. Nobuaki Suzuki · 8 shared papers, 2012–2017 · strength 0.37
  4. Hiroaki Nagano · 6 shared papers, 2016–2019 · strength 0.34
  5. Masaaki Oka · 7 shared papers, 2012–2017 · strength 0.30
  6. Kei Furuya · 1 shared paper, 2025 · strength 0.25
  7. Satoshi Matsukuma · 3 shared papers, 2016–2017 · strength 0.15
  8. 明 山内 · 1 shared paper, 2022 · strength 0.11
  9. Shuichiro Okamoto · 1 shared paper, 2022 · strength 0.11
  10. Masakiyo Sakaguchi · 1 shared paper, 2022 · strength 0.11
  11. Keisuke Hino · 1 shared paper, 2022 · strength 0.11
  12. Futoshi Kuribayashi · 1 shared paper, 2022 · strength 0.11
  13. Norihiko Sugisawa · 1 shared paper, 2022 · strength 0.11
  14. Robert M. Hoffman · 1 shared paper, 2022 · strength 0.11
  15. Masahiro Yamamura · 1 shared paper, 2022 · strength 0.11
  16. Haruo Iguchi · 2 shared papers, 2017 · strength 0.09
  17. Takashi Hatori · 2 shared papers, 2017 · strength 0.09
  18. Tetsuya Ikemoto · 2 shared papers, 2017 · strength 0.09
  19. Yuzo Umeda · 2 shared papers, 2017 · strength 0.09
  20. Mitsuo Shimada · 2 shared papers, 2017 · strength 0.09
  21. Yusuke Nakamura · 2 shared papers, 2017 · strength 0.09
  22. Toshiyoshi Fujiwara · 2 shared papers, 2017 · strength 0.09
  23. Masahiro Tanabe · 1 shared paper, 2019 · strength 0.08
  24. Yasuhiro Fujiwara · 1 shared paper, 2019 · strength 0.08
  25. Katsuyoshi Ito · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.